Gynecologic Oncology
RSSArticles
Postpartum LARCs help avert repeat pregnancy
The search has begun for long-acting contraceptives
FHI 360 has launched its Contraceptive Technology Innovation Initiative to develop innovative, long-acting contraceptives.Lower unintended pregnancy rates: Use IUD for emergency contraception
Women seeking emergency contraception (EC) are at high risk of unintended pregnancy.STI: Initial positive results reported on herpes vaccine — What’s next?
Some 776,000 U.S. residents incur new genital herpes infections annually. There is no cure. Initial, positive results are reported for a therapeutic vaccine candidate for treating genital herpes.Attacks continue on family planning funds
The last several years have brought unprecedented attacks on the publicly supported family planning effort in the United States.IUD for EC: Check the Utah experience
Can increased use of the copper T intrauterine device (ParaGard IUD, Teva Womens Health, North Wales, PA) for emergency contraception (EC) make an impact on the rate of unplanned pregnancy at your clinic?STI: HPV linked to rise in oropharyngeal cancer
Human papillomavirus (HPV) might be to blame for the rise of young adults with oropharyngeal cancer.STI: New report issued on antibiotic resistance
Enhance your practice by adding Selected Practice Recommendations
This new evidence-based guidance from the CDC will improve and streamline how we provide contraceptive services to our patients, says Andrew Kaunitz, MDNew intrauterine device now is in research
An experimental levonorgestrel 20 mcg intrauterine device (LNG20 IUD) is under development by Medicines360, a San Francisco-based nonprofit pharmaceutical company.